Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple antiemetic regimen for prevention of chemotherapy-induced nausea and vomiting during multi-day highly emetogenic chemotherapy
ChiCTR1900024816Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexamethasone in chemotherapy-induced nausea and vomiting (CINV), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Nausea, Complete remission rate of chemotherapy-induced nausea and vomiting and 1 more. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
dexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR1900024816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024816.